Mazdutide vs Tripeptide-29
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
MazdutideSkin & CosmeticAnti-Aging & Longevity
Tripeptide-29- Summary
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Tripeptide-29 is a pro-collagen cosmetic peptide composed of proline, hydroxyproline, and glycine — the core repeating unit of collagen. Applied topically, it signals dermal fibroblasts that collagen degradation has occurred, triggering compensatory new collagen synthesis.
- Half-Life
- ~7 days
- Not applicable (topical)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- 0.01-0.1% in formulation
- Frequency
- Once weekly
- Once or twice daily
- Key Benefits
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Stimulates fibroblast collagen synthesis via damage-signal mechanism
- Reduces fine lines and improves skin smoothness
- Supports dermal matrix integrity
- Naturally bioidentical to collagen fragment sequences
- Well-tolerated in all skin types
- Synergistic with copper peptides and retinoids
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Excellent tolerability profile
- No documented significant adverse effects at cosmetic concentrations
- Rare sensitivity reactions in individuals with peptide allergies
- Stacks With
- —
- —